Livzon Pharmaceutical Group Inc.

SZSE:000513 Stock Report

Market Cap: CN¥30.4b

Livzon Pharmaceutical Group Management

Management criteria checks 4/4

Livzon Pharmaceutical Group's CEO is Yanggang Tang, appointed in Dec 2018, has a tenure of 5.83 years. total yearly compensation is CN¥581.00K, comprised of 19.1% salary and 80.9% bonuses, including company stock and options. directly owns 0.038% of the company’s shares, worth CN¥11.58M. The average tenure of the management team and the board of directors is 10.5 years and 5.5 years respectively.

Key information

Yanggang Tang

Chief executive officer

CN¥581.0k

Total compensation

CEO salary percentage19.1%
CEO tenure6yrs
CEO ownership0.04%
Management average tenure10.5yrs
Board average tenure5.5yrs

Recent management updates

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Jun 07
We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Recent updates

We Think You Can Look Beyond Livzon Pharmaceutical Group's (SZSE:000513) Lackluster Earnings

Aug 30
We Think You Can Look Beyond Livzon Pharmaceutical Group's (SZSE:000513) Lackluster Earnings

Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 26
Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)

Aug 09
A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)

Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year

Jul 02
Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Jun 07
We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26
Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Apr 21
Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Mar 15
Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

CEO Compensation Analysis

How has Yanggang Tang's remuneration changed compared to Livzon Pharmaceutical Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

CN¥2b

Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥581kCN¥111k

CN¥2b

Sep 30 2023n/an/a

CN¥2b

Jun 30 2023n/an/a

CN¥2b

Mar 31 2023n/an/a

CN¥2b

Dec 31 2022CN¥520kn/a

CN¥2b

Sep 30 2022n/an/a

CN¥2b

Jun 30 2022n/an/a

CN¥2b

Mar 31 2022n/an/a

CN¥2b

Jan 01 2022n/an/a

CN¥2b

Sep 30 2021n/an/a

CN¥2b

Jun 30 2021n/an/a

CN¥2b

Mar 31 2021n/an/a

CN¥2b

Jan 01 2021n/an/a

CN¥2b

Sep 30 2020n/an/a

CN¥2b

Jun 30 2020n/an/a

CN¥2b

Mar 31 2020n/an/a

CN¥1b

Jan 01 2020n/an/a

CN¥1b

Sep 30 2019n/an/a

CN¥1b

Jun 30 2019n/an/a

CN¥1b

Mar 31 2019n/an/a

CN¥1b

Dec 31 2018CN¥3mCN¥800k

CN¥1b

Compensation vs Market: Yanggang's total compensation ($USD79.60K) is below average for companies of similar size in the CN market ($USD207.37K).

Compensation vs Earnings: Yanggang's compensation has been consistent with company performance over the past year.

CEO

Yanggang Tang (54 yo)

6yrs

Tenure

CN¥581,000

Compensation

Mr. Yanggang Tang has been President of Livzon Pharmaceutical Group since December 28, 2018 and serves as its Executive Director since February 14, 2019 and served as its Executive Vice President from July...

Leadership Team

NamePositionTenureCompensationOwnership
Yanggang Tang
President & Executive Director6yrsCN¥581.00k0.038%
CN¥ 11.6m
Guoxiang Xu
Executive Vice Chairman & VP of Sales7.5yrsCN¥547.19k0.086%
CN¥ 26.3m
Yanxia Si
VP & CFO10.5yrsCN¥354.39k0.045%
CN¥ 13.6m
Liang Yang
VP, Secretary to the Board & Company Secretary10.5yrsCN¥235.72k0.022%
CN¥ 6.8m
Daihong Yang
Vice President18.6yrsCN¥371.99k0.052%
CN¥ 15.7m
Yuxuan Huang
Vice President6.2yrsCN¥239.24k0.015%
CN¥ 4.5m
Jun Du
Vice President1.3yrsCN¥516.55k0.0055%
CN¥ 1.7m
Jianing Liu
Chief Investment Officer & Head of BD Dept.no datano datano data
Jianying Zhuang
Head of Accounting Departmentno datano datano data
Maolin Wang
Chief Supervisor and GM of Legal & Compliance23.9yrsCN¥405.80kno data
Daping Liu
Vice Presidentless than a yearno datano data

10.5yrs

Average Tenure

56yo

Average Age

Experienced Management: 000513's management team is seasoned and experienced (10.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yanggang Tang
President & Executive Director5.8yrsCN¥581.00k0.038%
CN¥ 11.6m
Guoxiang Xu
Executive Vice Chairman & VP of Sales7.5yrsCN¥547.19k0.086%
CN¥ 26.3m
Maolin Wang
Chief Supervisor and GM of Legal & Compliance14.9yrsCN¥405.80kno data
Qingfeng Qiu
Non-Executive Director17.7yrsCN¥9.60kno data
Baoguo Zhu
Non-Executive Chairman of the Board22.5yrsCN¥325.00kno data
Desheng Tao
Non-Executive Vice Chairman15.4yrsCN¥300.00k0.097%
CN¥ 29.5m
Qiusheng Tian
Independent Non-Executive Director5.2yrsCN¥12.00kno data
Hua Bai
Independent Non-Executive Director4.5yrsCN¥12.00kno data
Huiyuan Luo
Independent Non-Executive Director3.4yrsCN¥12.00kno data
Nanqi Lin
Non-Executive Directorless than a yearno datano data
Kam Wa Wong
Independent Non-Executive Director5.2yrsCN¥12.00kno data
Lijie Cui
Independent Non-Executive Director3.4yrsCN¥12.00kno data

5.5yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 000513's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 19:34
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Livzon Pharmaceutical Group Inc. is covered by 30 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Helena QiuCCB International Securities Limited
Shuchang LiuChangjiang Securities Co. LTD.